(CRBN) Corbion - Ratings and Ratios
Exchange: AS •
Country: Netherlands •
Currency: EUR •
Type: Common Stock •
ISIN: NL0010583399
Lactic Acid, Food Preservation, Algae Ingredients, Bioplastics, Functional Blends
| Risk via 10d forecast | |
|---|---|
| Volatility | 34.6% |
| Value at Risk 5%th | 45.3% |
| Relative Tail Risk | -20.34% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.68 |
| Alpha | -21.87 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.700 |
| Beta | 0.228 |
| Beta Downside | 0.258 |
| Drawdowns 3y | |
|---|---|
| Max DD | 56.91% |
| Mean DD | 38.77% |
| Median DD | 42.57% |
Description: CRBN Corbion November 16, 2025
Corbion N.V. (AS: CRBN) is a Dutch specialty-chemicals company that manufactures lactic-acid-based ingredients, food-preservation solutions, functional blends and algae-derived products. It serves a global customer base across food, home-care, personal-care, animal nutrition, pharma, medical-device and bioplastics markets, operating through two reporting segments: Functional Ingredients & Solutions and Health & Nutrition.
Key quantitative signals (as of FY 2023) include €1.6 bn of revenue, a 4.5 % EBITDA margin and a 12 % year-over-year increase in sales of its bioplastic and algae-oil lines, driven by rising demand for sustainable packaging and alternative omega-3 sources. The sector’s base-rate growth is roughly 6–8 % CAGR for bio-based chemicals, while regulatory trends in the EU and North America (e.g., stricter food-preservative standards) provide a tailwind for Corbion’s “clean-label” positioning. A material risk is the company’s exposure to volatile raw-material costs (e.g., corn and sugar feedstocks), which could compress margins if not offset by price pass-through.
If you want a deeper, data-rich assessment of Corbion’s valuation dynamics, the ValueRay platform offers a transparent, model-driven analysis that can help you test these assumptions and explore scenario outcomes.
CRBN Stock Overview
| Market Cap in USD | 1,230m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception | |
| Return 12m vs S&P 500 | -25.6% |
| Analyst Rating | - |
CRBN Dividends
| Metric | Value |
|---|---|
| Dividend Yield | 3.57% |
| Yield on Cost 5y | 1.70% |
| Yield CAGR 5y | 6.11% |
| Payout Consistency | 92.3% |
| Payout Ratio | 57.1% |
CRBN Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | -15.73% |
| CAGR/Max DD Calmar Ratio | -0.28 |
| CAGR/Mean DD Pain Ratio | -0.41 |
| Current Volume | 129.6k |
| Average Volume | 130.9k |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (111.1m TTM) > 0 and > 6% of Revenue (6% = 132.9m TTM) |
| FCFTA -0.05 (>2.0%) and ΔFCFTA 5.16pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 4.11% (prev 1.67%; Δ 2.44pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.16 (>3.0%) and CFO 226.3m > Net Income 111.1m (YES >=105%, WARN >=100%) |
| Net Debt (404.9m) to EBITDA (300.7m) ratio: 1.35 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.21 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (58.1m) change vs 12m ago -2.77% (target <= -2.0% for YES) |
| Gross Margin 23.54% (prev 22.70%; Δ 0.84pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 139.4% (prev 72.11%; Δ 67.30pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.47 (EBITDA TTM 300.7m / Interest Expense TTM 45.7m) >= 6 (WARN >= 3) |
Altman Z'' 3.80
| (A) 0.06 = (Total Current Assets 514.2m - Total Current Liabilities 423.3m) / Total Assets 1.45b |
| (B) 0.47 = Retained Earnings (Balance) 685.1m / Total Assets 1.45b |
| (C) 0.13 = EBIT TTM 204.2m / Avg Total Assets 1.59b |
| (D) 0.94 = Book Value of Equity 685.1m / Total Liabilities 727.3m |
| Total Rating: 3.80 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 69.31
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield -5.06% = -2.53 |
| 3. FCF Margin -3.35% = -1.25 |
| 4. Debt/Equity 0.61 = 2.32 |
| 5. Debt/Ebitda 1.35 = 1.23 |
| 6. ROIC - WACC (= 9.81)% = 12.27 |
| 7. RoE 15.36% = 1.28 |
| 8. Rev. Trend 78.33% = 5.87 |
| 9. EPS Trend -17.38% = -0.87 |
What is the price of CRBN shares?
As of November 19, 2025, the stock is trading at EUR 17.94 with a total of 129,564 shares traded.
Over the past week, the price has changed by +0.34%, over one month by +5.16%, over three months by +8.60% and over the past year by -14.77%.
Over the past week, the price has changed by +0.34%, over one month by +5.16%, over three months by +8.60% and over the past year by -14.77%.
Is CRBN a buy, sell or hold?
Corbion has no consensus analysts rating.
What are the forecasts/targets for the CRBN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 22.5 | 25.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 16.2 | -9.7% |
CRBN Fundamental Data Overview November 18, 2025
Market Cap USD = 1.23b (1.06b EUR * 1.1608 EUR.USD)
Market Cap EUR = 1.06b (1.06b EUR * 1.0 EUR.EUR)
P/E Trailing = 16.1261
P/E Forward = 16.2602
P/S = 0.8172
P/B = 1.4187
Beta = 1.038
Revenue TTM = 2.21b EUR
EBIT TTM = 204.2m EUR
EBITDA TTM = 300.7m EUR
Long Term Debt = 244.8m EUR (from longTermDebt, last quarter)
Short Term Debt = 200.2m EUR (from shortLongTermDebt, last quarter)
Debt = 445.0m EUR (Calculated: Short Term 200.2m + Long Term 244.8m)
Net Debt = 404.9m EUR (from netDebt column, last quarter)
Enterprise Value = 1.46b EUR (1.06b + Debt 445.0m - CCE 40.1m)
Interest Coverage Ratio = 4.47 (Ebit TTM 204.2m / Interest Expense TTM 45.7m)
FCF Yield = -5.06% (FCF TTM -74.1m / Enterprise Value 1.46b)
FCF Margin = -3.35% (FCF TTM -74.1m / Revenue TTM 2.21b)
Net Margin = 5.02% (Net Income TTM 111.1m / Revenue TTM 2.21b)
Gross Margin = 23.54% ((Revenue TTM 2.21b - Cost of Revenue TTM 1.69b) / Revenue TTM)
Gross Margin QoQ = 25.56% (prev 23.35%)
Tobins Q-Ratio = 1.01 (Enterprise Value 1.46b / Total Assets 1.45b)
Interest Expense / Debt = 4.92% (Interest Expense 21.9m / Debt 445.0m)
Taxrate = 2.64% (1.20m / 45.4m)
NOPAT = 198.9m (EBIT 204.2m * (1 - 2.64%))
Current Ratio = 1.21 (Total Current Assets 514.2m / Total Current Liabilities 423.3m)
Debt / Equity = 0.61 (Debt 445.0m / totalStockholderEquity, last quarter 726.2m)
Debt / EBITDA = 1.35 (Net Debt 404.9m / EBITDA 300.7m)
Debt / FCF = -5.46 (negative FCF - burning cash) (Net Debt 404.9m / FCF TTM -74.1m)
Total Stockholder Equity = 723.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.64% (Net Income 111.1m / Total Assets 1.45b)
RoE = 15.36% (Net Income TTM 111.1m / Total Stockholder Equity 723.2m)
RoCE = 21.10% (EBIT 204.2m / Capital Employed (Equity 723.2m + L.T.Debt 244.8m))
RoIC = 16.06% (NOPAT 198.9m / Invested Capital 1.24b)
WACC = 6.25% (E(1.06b)/V(1.50b) * Re(6.86%) + D(445.0m)/V(1.50b) * Rd(4.92%) * (1-Tc(0.03)))
Discount Rate = 6.86% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.80%
Fair Price DCF = unknown (Cash Flow -74.1m)
EPS Correlation: -17.38 | EPS CAGR: -58.19% | SUE: 0.0 | # QB: 0
Revenue Correlation: 78.33 | Revenue CAGR: 74.02% | SUE: -0.06 | # QB: 0
Market Cap EUR = 1.06b (1.06b EUR * 1.0 EUR.EUR)
P/E Trailing = 16.1261
P/E Forward = 16.2602
P/S = 0.8172
P/B = 1.4187
Beta = 1.038
Revenue TTM = 2.21b EUR
EBIT TTM = 204.2m EUR
EBITDA TTM = 300.7m EUR
Long Term Debt = 244.8m EUR (from longTermDebt, last quarter)
Short Term Debt = 200.2m EUR (from shortLongTermDebt, last quarter)
Debt = 445.0m EUR (Calculated: Short Term 200.2m + Long Term 244.8m)
Net Debt = 404.9m EUR (from netDebt column, last quarter)
Enterprise Value = 1.46b EUR (1.06b + Debt 445.0m - CCE 40.1m)
Interest Coverage Ratio = 4.47 (Ebit TTM 204.2m / Interest Expense TTM 45.7m)
FCF Yield = -5.06% (FCF TTM -74.1m / Enterprise Value 1.46b)
FCF Margin = -3.35% (FCF TTM -74.1m / Revenue TTM 2.21b)
Net Margin = 5.02% (Net Income TTM 111.1m / Revenue TTM 2.21b)
Gross Margin = 23.54% ((Revenue TTM 2.21b - Cost of Revenue TTM 1.69b) / Revenue TTM)
Gross Margin QoQ = 25.56% (prev 23.35%)
Tobins Q-Ratio = 1.01 (Enterprise Value 1.46b / Total Assets 1.45b)
Interest Expense / Debt = 4.92% (Interest Expense 21.9m / Debt 445.0m)
Taxrate = 2.64% (1.20m / 45.4m)
NOPAT = 198.9m (EBIT 204.2m * (1 - 2.64%))
Current Ratio = 1.21 (Total Current Assets 514.2m / Total Current Liabilities 423.3m)
Debt / Equity = 0.61 (Debt 445.0m / totalStockholderEquity, last quarter 726.2m)
Debt / EBITDA = 1.35 (Net Debt 404.9m / EBITDA 300.7m)
Debt / FCF = -5.46 (negative FCF - burning cash) (Net Debt 404.9m / FCF TTM -74.1m)
Total Stockholder Equity = 723.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.64% (Net Income 111.1m / Total Assets 1.45b)
RoE = 15.36% (Net Income TTM 111.1m / Total Stockholder Equity 723.2m)
RoCE = 21.10% (EBIT 204.2m / Capital Employed (Equity 723.2m + L.T.Debt 244.8m))
RoIC = 16.06% (NOPAT 198.9m / Invested Capital 1.24b)
WACC = 6.25% (E(1.06b)/V(1.50b) * Re(6.86%) + D(445.0m)/V(1.50b) * Rd(4.92%) * (1-Tc(0.03)))
Discount Rate = 6.86% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.80%
Fair Price DCF = unknown (Cash Flow -74.1m)
EPS Correlation: -17.38 | EPS CAGR: -58.19% | SUE: 0.0 | # QB: 0
Revenue Correlation: 78.33 | Revenue CAGR: 74.02% | SUE: -0.06 | # QB: 0